Skip main navigation

Anti-Hemophilic Factors


Most of the recombinant factor VIII products currently on the market incorporate proteins or raw materials derived from either human or animal sources. Next-generation recombinant factor VIII for the treatment of hemophilia A is produced using a protein-free manufacturing process. By excluding proteins or raw materials derived from human or animal sources in the final product, the risk of transmission of potentially infectious agents is greatly diminished.

Recombinant AHF (r-AHF) is a recombinant anti-hemophilic factor derived from Chinese Hamster Ovary (CHO) cell line. Recombinant factor VIII is indicated for Hemophilia A, that of Factor IX for Hemophilia B. A list of then new approved r-AHF (2014) is presented Different brands of r-AHF contain different dose units, caution should be exercised to avoid dispensing error (e.g., Alprolix vs Kogenate vs BeneFix, 1000/2000/3000 iu).

This article is from the free online

Pharmacotherapy: Understanding Biotechnology Products

Created by
FutureLearn - Learning For Life

Reach your personal and professional goals

Unlock access to hundreds of expert online courses and degrees from top universities and educators to gain accredited qualifications and professional CV-building certificates.

Join over 18 million learners to launch, switch or build upon your career, all at your own pace, across a wide range of topic areas.

Start Learning now